Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in early patient trials . Current examination https://bookmarkfriend.com/story21397289/retatrutide-emerging-research-and-possible-clinical-roles